Amgen Inc., of Thousand Oaks, Calif., reported revenue of $5.81 billion in the second quarter, up 2 percent year over year and beating consensus of $5.69 billion. Sales of top-selling anti-inflammatory Enbrel (etanercept) slipped 1 percent year over year to $1.47 billion while sales of bone marrow stimulant Neulasta (pegfilgrastim) decreased 5 percent to $1.09 billion.